Creating anti-infective
opportunities
"Patients are at the heart of what we do"
Investor presentation
April 9, 2024
Table of contents
- Executive summary
- Portfolio
- Antifungals
- Cresemba® (isavuconazole)
- Fosmanogepix
- BAL2062
- Antibiotic
- Zevtera® (ceftobiprole)
- Tonabacase
- Financials & Outlook
- Appendix
Creating anti-infective opportunities | Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 2 |
Executive summary
Experienced leadership team
Creating anti-infective opportunities | Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 4 |
At a glance
- Focus on the treatment of severe bacterial and fungal infections
- Recognized ability to establish and manage partnerships in both the development and commercial phase
- Cresemba® and Zevtera® - two revenue generating hospital anti-infective brands
- Commercial products complemented by clinical and preclinical programs, including
- Fosmanogepix, a phase-3-readybroad-spectrum antifungal
- BAL2062, an antifungal for the potential treatment of invasive aspergillosis
- Tonabacase, an endolysin antibacterial for the potential treatment of severe staphylococcal infections
- Profitable biotech company listed on SIX Swiss Stock Exchange, SIX: BSLN
- Located in the Basel area life sciences hub, Switzerland
Creating anti-infective opportunities | Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 5 |
Innovative anti-infective pipeline
- The registration status and approved indications may vary from country to country.
- Formerly GR-2397
- Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
- Exclusive option to in-license upon completion of preclinical profiling
- CARB-X'sfunding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).
Creating anti-infective opportunities | Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 6 |
Global coverage - Cresemba®
Over 100 countries covered by partnerships
Creating anti-infective opportunities | Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 7 |
The company we keep - Established strong partnerships
Double-digit percentage royalties on sales by license partners
Participation | |
in sales of | |
distribution | |
partners | |
through | |
>CHF 1 bn | transfer price |
in potential | |
milestones | |
remaining |
>CHF 355 mn
upfront and
milestone payments received
Creating anti-infective opportunities | Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 8 |
Antifungal
Cresemba® (isavuconazole)
Invasive mold infections
The market - Invasive fungal infections
- Severe, potentially life-threatening infections mainly affecting immunocompromised patients
- An important cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens
- Rising number of immunocompromised patients (cancer and transplantations) driving therapeutic demand
- Mucorales infections on the rise - doubled from 2000 to 2013
- Limitations of current therapies (spectrum of activity, toxicity, effective plasma levels) drive the need for new agents
**Kullberg/Arendrup N Engl J Med 2015, Baddley Clin Infect Dis 2010, Roden Clin Infect Dis 2005, Greenberg Curr Opin Infect Dis 2004.
Creating anti-infective opportunities | Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Basilea Pharmaceutica AG published this content on 08 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 April 2024 05:21:01 UTC.